What is the dose of Unasyn (Ampicillin/Sulbactam) for a patient with normal renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Unasyn (Ampicillin/Sulbactam) Dosing for Normal Renal Function

For adults with normal renal function, the standard dose of Unasyn is 1.5 to 3 grams (1 to 2 grams ampicillin plus 0.5 to 1 gram sulbactam) administered intravenously every 6 hours, with a maximum daily dose of 12 grams (8 grams ampicillin plus 4 grams sulbactam). 1

Standard Adult Dosing Regimens

Intravenous Administration:

  • Mild to moderate infections: 1.5 grams (1 gram ampicillin/0.5 gram sulbactam) IV every 6 hours 1
  • Moderate to severe infections: 3 grams (2 grams ampicillin/1 gram sulbactam) IV every 6 hours 1, 2
  • Maximum daily dose: 12 grams total (8 grams ampicillin/4 grams sulbactam) 1

Intramuscular Administration:

  • 1.5 grams (1 gram ampicillin/0.5 gram sulbactam) IM can be used when IV access is not available 1
  • Peak serum levels after IM injection range from 8 to 37 mcg/mL for ampicillin and 6 to 24 mcg/mL for sulbactam 1

Pharmacokinetic Considerations

Timing and Peak Levels:

  • Peak serum concentrations are achieved immediately after a 15-minute IV infusion 1
  • After 2 grams ampicillin/1 gram sulbactam IV: peak ampicillin levels reach 109-150 mcg/mL and sulbactam levels reach 48-88 mcg/mL 1
  • After 1 gram ampicillin/0.5 gram sulbactam IV: peak ampicillin levels reach 40-71 mcg/mL and sulbactam levels reach 21-40 mcg/mL 1

Elimination:

  • Mean serum half-life is approximately 1 hour for both ampicillin and sulbactam in healthy volunteers 1
  • 75-85% of both drugs are excreted unchanged in urine during the first 8 hours after administration 1
  • Ampicillin is approximately 28% protein-bound and sulbactam is approximately 38% protein-bound 1

Pediatric Dosing

For pediatric patients with normal renal function:

  • Standard dose: 50 to 75 mg/kg body weight (combined ampicillin/sulbactam) administered IV every 6 hours 1
  • Peak serum concentrations after 15-minute infusion: 82-446 mcg/mL for ampicillin and 44-203 mcg/mL for sulbactam 1
  • Mean half-life is approximately 1 hour, similar to adults 1

Clinical Application by Infection Type

Urogenital Infections:

  • Average daily dose of 6 to 9 grams total (administered as divided doses every 6 hours) for 7-10 days 2
  • Clinical and bacteriological efficacy of 95% demonstrated in acute pyelonephritis 2
  • Excellent efficacy against gram-positive flora and E. coli; satisfactory results against Proteus species 2

Oral Formulation (Sultamicillin):

  • For mild to moderate infections when oral therapy is appropriate: 375 mg tablets twice daily 3
  • Pediatric oral dose: 50 mg/kg per day divided into doses 4
  • Mean treatment duration: 7.4 days (range 4-14 days) 4

Important Clinical Considerations

Tissue Penetration:

  • Unasyn achieves therapeutic levels in peritoneal fluid, blister fluid, intestinal mucosa, and appendix 1
  • Both ampicillin and sulbactam penetrate into cerebrospinal fluid in the presence of inflamed meninges 1

Administration Technique:

  • Administer IV infusion over 15 minutes to achieve optimal peak concentrations 1, 5
  • When using IM route, expect pain at injection site as the most common adverse effect 2

Common Pitfall to Avoid:

  • Do not reduce dosing frequency in patients with normal renal function—the every 6-hour interval is essential to maintain therapeutic levels given the 1-hour half-life 1
  • Ensure adequate hydration to support renal elimination of 75-85% of the drug 1

References

Research

[The use of ampicillin/sulbactam (Unasyn) in treating inflammatory urological diseases].

Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1991

Research

Observations on oral Sultamicillin/Unasyn CP-45 899 therapy of neonatal infections.

International journal of antimicrobial agents, 1997

Research

Unasyn (ampicillin sodium/sulbactam sodium).

Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.